MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design

G Landoni, V Lomivorotov, A Pisano, C Nigro Neto, U Benedetto, G Biondi Zoccai, M Gemma, S Frassoni, FE Agrò, Massimo Baiocchi, FR Barbosa Gomes Galas, A Bautin, N Bradic, Cristiana Carollo, G Crescenzi, AM Elnakera, MR El-Tahan, Evgeny Fominskiy, AG Farag, G GazivodaStefano Gianni, E Grigoryev, Fabio Guarracino, S Hanafi, W Huang, G Kunst, J Kunstyr, C Lei, R Lembo, Zj Li, V Likhvantsev, A Lozovskiy, J Ma, F Monaco, P Navalesi, B Nazar, V Pasyuga, Elena Porteri, C Royse, Laura Ruggeri, H Riha, F Santos Silva, Luca Severi, V Shmyrev, N Uvaliev, CB Wang, CY Wang, D Winterton, CY Yong, J Yu, Rinaldo Bellomo, A Zangrillo

Research output: Contribution to journalArticle

Abstract

Objective There is initial evidence that the use of vola tile anesthetics can reduce the postoperative release of cardiac troponin I, the need for inotropic support, and the number of patients requiring prolonged hospitalization following coronary artery bypass graft (CABG) surgery. Nevertheless, small randomized controlled trials have failed to demonstrate a survival advantage. Thus, whether volatile anesthetics improve the postoperative outcome of cardiac surgical patients remains uncertain. An adequately powered randomized controlled trial appears desirable. Design Single blinded, international, multicenter randomized controlled trial with 1:1 allocation ratio. Setting Tertiary and University hospitals. Interventions Patients (n = 10,600) undergoing coronary artery bypass graft will be randomized to receive either volatile anesthetic as part of the anesthetic plan, or total intravenous anesthesia. Measurements and main results The primary end point of the study will be one-year mortality (any cause). Secondary endpoints will be 30-day mortality; 30-day death or non-fatal myocardial infarction (composite endpoint); cardiac mortality at 30 day and at one year; incidence of hospital re-admission during the one year follow-up period and duration of intensive care unit, and hospital stay. The sample size is based on the hypothesis that volatile anesthetics will reduce 1-year unadjusted mortality from 3% to 2%, using a two-sided alpha error of 0.05, and a power of 0.9. Conclusions The trial will determine whether the simple intervention of adding a volatile anesthetic, an intervention that can be implemented by all anesthesiologists, can improve one-year survival in patients undergoing coronary artery bypass graft surgery. © 2017 Elsevier Inc.
Original languageEnglish
Pages (from-to)38-43
Number of pages6
JournalContemporary Clinical Trials
Volume59
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint Dive into the research topics of 'MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design'. Together they form a unique fingerprint.

  • Cite this

    Landoni, G., Lomivorotov, V., Pisano, A., Nigro Neto, C., Benedetto, U., Biondi Zoccai, G., Gemma, M., Frassoni, S., Agrò, FE., Baiocchi, M., Barbosa Gomes Galas, FR., Bautin, A., Bradic, N., Carollo, C., Crescenzi, G., Elnakera, AM., El-Tahan, MR., Fominskiy, E., Farag, AG., ... Zangrillo, A. (2017). MortalitY in caRdIAc surgery (MYRIAD): A randomizeD controlled trial of volatile anesthetics. Rationale and design. Contemporary Clinical Trials, 59(1), 38-43. https://doi.org/10.1016/j.cct.2017.05.011